BIBLIOS

  Ciências References Management System

Visitor Mode (Login)
Need help?


Back

Publication details

Document type
Other

Document subtype
Executive summary

Title
Alternative therapeutic strategies to the treatment of drug-refractory temporal lobe epilepsy

Participants in the publication
D Cunha-Reis (Author)
Dep. Biologia Vegetal
BioISI

Summary
This project proposes to evaluate the therapeutic potential of three different strategies for mesial temporal-lobe epilepsy with hippocampal sclerosis (MTLE-HS). These three distinct approaches are aimed at to two specific aspects of disease pathology: 1) altered hippocampal synaptic plasticity mechanisms and 2) hippocampal GABAergic interneuron survival/adaptation, which is dependent on the activity of extrinsic projections to these interneurons. Vasoactive intestinal peptide (VIP) VPAC1 receptor ligands will be used to target early synaptic plasticity changes leading to epileptogenesis and contributing to selective interneuron death. Mismatch novelty training will be used to rescue altered synaptic plasticity in the chronic phase of MTLE and rescue median raphe serotonergic and septal GABAergic extrinsic innervation of the hippocampus. MTLE impact on membrane lipid composition, synaptic lipid raft dynamics, and consequences for synaptic plasticity aims to determine if synapses and neuronal membranes are important therapeutic targets of ketogenic diet therapy.

Date of Publication
2019-07-01

Publication Identifiers

Publisher
Fundacao para a Ciencia e a Tecnologia (unidadeFCCN)

Document Identifiers
DOI - https://doi.org/10.54499/dl57/2016/cp1479/ct0044
URL - http://dx.doi.org/10.54499/dl57/2016/cp1479/ct0044


Export

APA
D Cunha-Reis, (2019). Alternative therapeutic strategies to the treatment of drug-refractory temporal lobe epilepsy

IEEE
D Cunha-Reis, "Alternative therapeutic strategies to the treatment of drug-refractory temporal lobe epilepsy", 2019

BIBTEX
@misc{59870, author = {D Cunha-Reis}, title = {Alternative therapeutic strategies to the treatment of drug-refractory temporal lobe epilepsy}, year = 2019 }